NASDAQ:STOK Stoke Therapeutics Q1 2025 Earnings Report $8.93 -0.73 (-7.56%) As of 05/13/2025 04:00 PM Eastern Earnings HistoryForecast Stoke Therapeutics EPS ResultsActual EPS$1.90Consensus EPS -$0.37Beat/MissBeat by +$2.27One Year Ago EPSN/AStoke Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AStoke Therapeutics Announcement DetailsQuarterQ1 2025Date5/13/2025TimeBefore Market OpensConference Call DateTuesday, May 13, 2025Conference Call Time7:30AM ETConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Stoke Therapeutics Earnings HeadlinesStoke Therapeutics, Inc. (NASDAQ:STOK) Receives $25.60 Consensus PT from BrokeragesMay 14 at 1:35 AM | americanbankingnews.comNeedham Keeps Their Buy Rating on Stoke Therapeutics (STOK)April 10, 2025 | markets.businessinsider.comWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... Just did a demo of what Nvidia’s CEO said will be "the first multitrillion-dollar robotics industry."May 14, 2025 | Brownstone Research (Ad)Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | businesswire.comStoke Therapeutics remains significantly undervalued, says CanaccordApril 1, 2025 | markets.businessinsider.comEarnings Beat: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their ForecastsMarch 22, 2025 | finance.yahoo.comSee More Stoke Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Stoke Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Stoke Therapeutics and other key companies, straight to your email. Email Address About Stoke TherapeuticsStoke Therapeutics (NASDAQ:STOK), an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy. The company also develops STK-001, which is in phase I/II clinical trial to treat Dravet syndrome; and programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye. The company has a license and collaboration agreement with Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of severe and rare genetic neurodevelopmental diseases of the central nervous system. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.View Stoke Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery?Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Upcoming Earnings Copart (5/15/2025)NetEase (5/15/2025)Applied Materials (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Palo Alto Networks (5/19/2025)PDD (5/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
